Acurian Quickly Closes a Critical Enrollment Gap for an IBS Study

This small pharmaceutical company was in a race to be first to market for diarrhea-predominant Irritable Bowel Syndrome (IBS), a market with multi-billion dollar potential. An 11-month enrollment timeline was critical to the successful completion of a two-protocol, phase III program.

Gastroenterology

We make gastroenterology trials less painful…and easier to digest.

Our success is a combination of aligning the enrollment process with today’s realities, customized solutions, and true insight into site relationships. From OIC/OIBD, IBS and GERD, to Crohn’s disease, Acurian makes trials a lot less trying.

Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.